- Atossa Therapeutics will hold its annual stockholders meeting as a virtual meeting on May 7, 2026.
- Items to be voted on include electing three Class II directors: Stephen Galli, Richard Steinhart and Tessa Cigler.
- Shareholders will also vote on ratifying Ernst & Young as the independent registered public accounting firm.
- Another proposal seeks approval to amend the certificate of incorporation to allow a reverse stock split at a ratio between 2:1 and 20:1.
- Additional votes cover an advisory say-on-pay resolution and a proposal to adjourn the meeting if needed to solicit additional proxies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-117826), on March 20, 2026, and is solely responsible for the information contained therein.
Comments